UPDATE 1-TABLE-Abraxis BioScience Q4 earnings rise

(Adds 2007 outlook)

Feb 26 (Reuters) -

ABRAXIS BIOSCIENCE INC. ABBI.O

Latest Forecast* No. of Yr ago

analysts qtr
EPS (diluted, $/shr) 0.18 -- -- 0.02
EPS, pre ex#(dil, $/shr) 0.29 -- -- 0.09
Net ($ million) 28.4 -- -- 2.6
Net sales ($ million) 257.1 204.9 3 145.6

*Source: Reuters Estimates

#Excludes merger-related items and non-cash stock
compensation expense

--For the latest fourth quarter, three analysts on average
had expected the company to earn 16 cents a share, excluding
any exceptional items but including stock options expense,
according to Reuters Estimates.

--For full year 2007, the company said it expects net sales
for its Abraxane cancer drug to be between $285 million and
$305 million, versus $174.9 million posted in 2006.

--The company expects R&D expenses in 2007 of between $100
million and $110 million.
(Reporting by Shailesh Kuber in Bangalore)